Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) EBITDA (2016 - 2025)

Historic EBITDA for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $5.3 million.

  • Lifecore Biomedical, Inc. \De\'s EBITDA rose 14788.27% to $5.3 million in Q2 2025 from the same period last year, while for May 2025 it was -$17.2 million, marking a year-over-year decrease of 18117.2%. This contributed to the annual value of -$17.2 million for FY2025, which is 9499.1% down from last year.
  • According to the latest figures from Q2 2025, Lifecore Biomedical, Inc. \De\'s EBITDA is $5.3 million, which was up 14788.27% from -$9.0 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical, Inc. \De\'s EBITDA ranged from a high of $15.6 million in Q1 2024 and a low of -$36.5 million during Q1 2023
  • Moreover, its 5-year median value for EBITDA was -$4.6 million (2022), whereas its average is -$4.4 million.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s EBITDA plummeted by 1330273.97% in 2022 and then soared by 21356.23% in 2023.
  • Lifecore Biomedical, Inc. \De\'s EBITDA (Quarter) stood at $3.7 million in 2021, then plummeted by 439.3% to -$12.5 million in 2022, then skyrocketed by 213.56% to $14.2 million in 2023, then tumbled by 113.78% to -$2.0 million in 2024, then surged by 371.92% to $5.3 million in 2025.
  • Its last three reported values are $5.3 million in Q2 2025, -$9.0 million for Q1 2025, and -$2.0 million during Q4 2024.